



SIMPLE EXTRACTION OF GAMMA-HYDROXYBUTYRATE IN HUMAN WHOLE BLOOD BY HEADSPACE SOLID-PHASE MICROEXTRACTION

メタデータ	<p>言語: English</p> <p>出版者: 日本法中毒学会</p> <p>公開日: 2013-08-27</p> <p>キーワード (Ja):</p> <p>キーワード (En):</p> <p>作成者: Kurihara, Rina, Ishii, Akira, Watanabe, Kanako, Kumazawa, Takeshi, Seno, Hiroshi, Suzuki, Osamu, Katsumata, Yoshinao, Suzuki, Kanako</p> <p>メールアドレス:</p> <p>所属:</p>
URL	<p>http://hdl.handle.net/10271/1728</p>

SIMPLE EXTRACTION OF GAMMA-HYDROXYBUTYRATE IN HUMAN WHOLE BLOOD BY HEADSPACE SOLID-PHASE MICROEXTRACTION

Rina KURIHARA^{a*}, Akira ISHII^a, Kanako WATANABE-SUZUKI^b,
Takeshi KUMAZAWA^c, Hiroshi SENO^d, Osamu SUZUKI^b and Yoshinao KATSUMATA^a

^a Department of Legal Medicine and Bioethics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 464-8550, Japan

^b Department of Legal Medicine, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu 431-3192, Japan

^c Department of Legal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan

^d Department of Legal Medicine, Aichi Medical University, 21 Karimata, Yazako, Nagakute-cho, Aichi-gun, Aichi 480-1195, Japan

Received November 21, 2000

Accepted December 15, 2000

ヘッドスペース固相マイクロ抽出を用いた全血中ガンマヒドロキシ酪酸 (GHB) の簡便抽出法

栗原リナ^{a*}, 石井 晃^a, 鈴木(渡部)加奈子^b, 熊澤武志^c, 妹尾 洋^d, 鈴木 修^b, 勝又義直^a

^a 名古屋大学医学部法医学教室 〒466-8550 愛知県名古屋市昭和区鶴舞町65

^b 浜松医科大学法医学教室 〒431-3192 静岡県浜松市半田町3600番地

^c 昭和大学医学部法医学教室 〒142-8555 東京都品川区旗の台1丁目5番8号

^d 愛知医科大学法医学教室 〒480-1195 愛知県愛知郡長久手町岩作雁又21

Summary

We have developed a simple method for the extraction of gamma-hydroxybutyrate (GHB) in human whole blood using headspace solid-phase microextraction (SPME). The procedure involves the conversion of GHB to gamma-butyrolactone (GBL) with acid catalysis; gamma-valerolactone (GVL) was used as internal standard (IS). After heating a vial containing a whole blood sample with GHB and IS at 80°C for 5 min in the presence of H₃PO₄ solution, a Carboxen/polydimethylsiloxane-coated fiber was exposed to the headspace to allow adsorption of GBL and IS. The fiber needle was then injected into a capillary gas chromatography port. Although the extraction efficiency of GHB was no more than 0.68%, the calibration curve showed good linearity in the range of 10–200 µg/ml, and intra-day and inter-day assay coefficients of variation were 3.29 and 4.14%, respectively. The detection limit was about 2 µg/ml. The present SPME method for GHB is sensitive enough to be adopted in forensic toxicology and clinical pharmacology.

Key words: Solid-phase microextraction; Headspace method; Gas chromatography; Gamma-hydroxybutyrate; Gamma-butyrolactone; Gamma-valerolactone

*To whom all correspondence should be addressed.

©2001 Japanese Association of Forensic Toxicology. All rights reserved. 0915-9606/01/ \$ 11.00

Introduction

Gamma-hydroxybutyrate (GHB) is an endogenous substance which is thought to be a neurotransmitter [1]. When administered as a drug, it produces diverse pharmacological effects, such as sleep induction [2], increased brain dopamine [3] and glucose levels [4], euphoric reactions [5] and stimulating the release of growth hormone and prolactin [6].

Due to these effects, GHB has been used for various purposes. In Europe it was once used as an anaesthetic, but now it is used for treatments of narcolepsy [7, 8], alcoholism [9, 10] and opiate withdrawal syndrome [11]. In the United States, it had been available as an over-the-counter medicine for inducing sleep and sold in health food stores as an aid for arriving at euphoric state, muscular development, weight loss and anti-aging, before Food and Drug Administration (FDA) of the United States banned its marketing in 1990 [12]. In spite of its serious side effects, such as dizziness, vomiting, disorientation, seizures, hypotension, bradycardia, coma and respiratory depression, GHB abuse is on the rise and is associated with driving under influence cases [13, 14] and sexual assaults [15]. Deaths caused by GHB intoxication were also reported [16–18]. Thus, simple and accurate methods to analyze GHB are needed.

Solid-phase microextraction (SPME), a new and simple extraction method, was first introduced by Arthur and Pawliszyn in 1990 [19]. Our group has applied the method to analyses of many drugs and poisons [20–24]. In this report, we present a simple method for extraction of GHB from whole blood by SPME prior to analysis by gas chromatography (GC).

Experimental

Materials

GHB sodium salt was purchased from Sigma (St. Louis, MO, USA); gamma-butyrolactone (GBL) and gamma-valerolactone (GVL) from Aldrich (Milwaukee, WI, USA). SPME devices and their five types of fiber assemblies, *i.e.*, 65 μm Carboxen/polydimethylsiloxane (CAR/PDMS), 100 μm polydimethylsiloxane (PDMS), 65 μm polydimethylsiloxane/divinylbenzene (PDMS/DVB), 85 μm polyacrylate and 65 μm Carbowax/divinylbenzene (CW/DVB) coated fibers, were purchased from Supelco Inc. (Bellefonte, PA, USA), and an Rtx-Volatiles fused silica capillary column (30 m \times 0.32 mm ID, film thickness 1.5 μm) from Restek (Bellefonte, PA, USA). Other common chemicals used were of the analytical grade. Whole blood was obtained from healthy volunteers.

Extraction procedure

To 0.5 ml of whole blood containing 50 μg GHB and 12.5 μg GVL, which had been placed in

a 7-ml vial with a small Teflon-coated stirring bar, were added 1.1 ml distilled water, 1.5 g Na_2SO_4 and 0.4 ml of 50% H_3PO_4 . The vial was sealed with a silicone septum cap and placed on an aluminum block heater set at 80°C. After 5 min, the needle of the SPME fiber holder was passed through the septum. Then the fiber in the needle was pushed out and exposed to the headspace of the vial at 80°C for 30 min before the fiber was pulled back into the needle. The needle containing the fiber was then quickly pulled out of the septum, and inserted into the gas chromatograph port; the fiber was again pushed out. The needle with the exposed fiber was held there for 3 min before being pulled out of the chromatograph.

GC conditions

GC analysis was performed on a Shimadzu (Kyoto) GC-14B equipped with a flame ionization detector (FID). The column temperature was held at 100°C for 1 min after injection and then programmed to 250°C at 10°C/min. Injector and detector temperatures were 240 and 280°C, respectively, and the helium flow rate was about 2.0 ml/min. The injection port was set in the splitless mode, and the splitter was opened 1 min after the insertion of the SPME fiber.

Results

Figure 1 shows the typical gas chromatograms. The left panel shows the authentic GBL and IS dissolved in methanol (200 ng each on-column), and the right one shows the headspace SPME extract from human whole blood containing spiked GHB (100 $\mu\text{g}/\text{ml}$) and IS (25 $\mu\text{g}/\text{ml}$). The retention times were 8.7 min for GBL and 9.3 min for IS. No endogenous GHB was detected as shown in whole blood blank (middle panel).

The extraction efficiencies for GHB were 0.68% for 10 $\mu\text{g}/\text{ml}$ and 0.60% for 100 $\mu\text{g}/\text{ml}$ GHB; they were calculated by comparing the peak areas for the SPME extract with that for the authentic GBL dissolved in methanol.

We tested other types of SPME fibers, such as PDMS, PDMS/DVB, polyacrylate and CW/DVB; their extraction efficiencies were less than 10% as compared with that of the CAR/PDMS-coated fiber (Fig. 2). We also tried some salts to obtain the highest efficiency; Na_2SO_4 gave higher efficiency than $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ or NaCl . The optimum amount of Na_2SO_4 was found to be 1.5–2.0g in a vial. We tested various temperatures, such as 60, 65, 70, 75, 80, 85, 90 and 95°C, and got the best GHB efficiency at 80°C (data not shown).

The calibration curve was drawn by plotting six different points in the range of 10–200 $\mu\text{g}/\text{ml}$. It gave good linearity, and the equation was $y = -0.00102 + 0.00926 x$ with the r value of 0.995. The detection limit of GHB was about 2 $\mu\text{g}/\text{ml}$.

The coefficients of variation (CVs) for intra-day measurements ($n=4$) were 2.67% (20 $\mu\text{g}/\text{ml}$




Fig. 1. Gas chromatograms for 200 ng of the non-extracted authentic GBL (filled arrow) and IS (open arrow) dissolved in methanol with direct injection (left panel), the headspace SPME extracts from human whole blood containing spiked 100 $\mu\text{g/ml}$ of GHB (filled arrow) and 25 $\mu\text{g/ml}$ of IS (open arrow) (right panel) and whole blood blank (middle panel).




Fig. 2. Comparison of five SPME fiber coatings, *i.e.*, Carboxen/polydimethylsiloxane (CAR/PDMS), polydimethylsiloxane (PDMS), polydimethylsiloxane/divinylbenzene (PDMS/DVB), polyacrylate and Carbowax/divinylbenzene (CW/DVB) for extraction of GHB from whole blood (100 $\mu\text{g/ml}$). Each SPME fiber was exposed to the headspace of the sample solution for 30 min at 80°C. The amount of GHB extracted by the CAR/PDMS fiber was set at 100%.

GHB) and 3.29% (100 $\mu\text{g}/\text{ml}$ GHB), and inter-day CVs ($n=4$) were 4.14% (20 $\mu\text{g}/\text{ml}$ GHB) and 3.95% (100 $\mu\text{g}/\text{ml}$ GHB).

Discussion

In this report, we have presented a simple method for extraction of GHB in human whole blood using SPME. Owing to the high polarity of GHB, it was converted to GBL by acid catalysis before extraction in many methods [25–30]. In some reports, the extraction of GHB is followed by derivatization for GC analysis to detect GHB without such conversion [14, 31–35].

It was reported that there were no significant levels of endogenous GBL in blood [28]; there was no enzymatic or chemical formation of GBL formation from GHB [28, 29]. Hence we have adopted the conversion technique by acid catalysis to avoid complicated preparations.

Very recently, Aspelund *et al.* [36] have demonstrated a method of GHB analysis using SPME with a Carbowax/templated resin-coated fiber and capillary gas chromatography with FID. The detection limit of our method is almost comparable to that of theirs.

It was reported that 33 and 34 $\mu\text{g}/\text{ml}$ blood concentrations of GHB were associated with driving under influence (DUI), 130–220 $\mu\text{g}/\text{ml}$ associated with toxic effects [14] and 300 $\mu\text{g}/\text{ml}$ associated with lethal effects [18]. Thus the present method is sufficiently applicable to the measurements of the drug at therapeutic or toxic levels.

In conclusion, our method has proved to be recommendable for actual clinical and toxic cases, because of its simplicity, accuracy and sufficient sensitivity.

Acknowledgement

This work was supported by the research grant of Uehara Memorial Foundation.

References

- 1) Vayer, P., Mandel, P. and Maitre, M.: Gamma-hydroxybutyrate, a possible neurotransmitter. *Life Sci*, **41**, 1547–1557 (1987).
- 2) Bessman, S. P. and Skolnik, S. J.: Gamma-hydroxybutyrate and gamma-butyrolactone: concentration in rat tissues during anesthesia. *Science*, **143**, 1045–1047 (1964).
- 3) Gessa, G. L., Vargiu, L., Crabai, F., Boero, G. C., Caboni, F. and Camba, R.: Selective increase of brain dopamine induced by gamma-hydroxybutyrate. *Life Sci*, **5**, 1921–1930 (1966).
- 4) Wolfson, L. I., Sakurada, O. and Sokoloff, L.: Effects of γ -butyrolactone on local cerebral glucose utilization in the rat. *J Neurochem*, **29**, 777–783 (1977).
- 5) Galloway, G. P., Frederick, S. L., Staggers, F. E., Gonzales, M., Stalcup, S. A. and Smith, D. E.: Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. *Addiction*, **92**, 89–96 (1997).

- 6) Takahara, J., Yunoki, S., Yakushiji, W., Yamauchi, J., Yamane, Y. and Ofuji, T.: Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. *J Clin Endocrinol Metab*, **44**, 1014–1017 (1977).
- 7) Mamelak, M., Scharf, M. B. and Woods, M.: Treatment of narcolepsy with γ -hydroxybutyrate. A review of clinical and sleep laboratory findings. *Sleep*, **9**, 285–289 (1986).
- 8) Lammers, G. J., Arends, J., Declerck, A. C., Ferrari, M. D., Schouwink, G. and Troost, J.: Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. *Sleep*, **16**, 216–220 (1993).
- 9) Gallimberti, L., Canton, G., Gentile, N., Ferri, M., Cibir, M., Ferrara, S. D., Fadda, F. and Gessa, G. L.: Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. *Lancet*, **II**, 787–789 (1989).
- 10) Poldrugo, F. and Addolorato, G.: The role of γ -hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. *Alcohol Alcoholism*, **34**, 15–24 (1999).
- 11) Gallimberti, L., Cibir, M., Pagnin, P., Sabbion, R., Pani, P. P., Pirastu, R., Ferrara, S. D. and Gessa, G. L.: Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. *Neuropsychopharmacology*, **9**, 77–81 (1993).
- 12) Auerbach, S. B., Noji, E. K. and Falk, H.: Gamma hydroxy butyrate (GHB). *J Am Med Assoc*, **265**, 2959 (1991).
- 13) Stephens, B. G. and Baselt, R. C.: Driving under the influence of GHB? *J Anal Toxicol*, **18**, 357–358 (1994).
- 14) Couper, F. J. and Logan, B. K.: Determination of γ -hydroxybutyrate (GHB) in biological specimens by gas chromatography-mass spectrometry. *J Anal Toxicol*, **24**, 1–7 (2000).
- 15) Elsohly, M. A. and Salamone, S. J.: Prevalence of drugs used in cases of alleged sexual assault. *J Anal Toxicol*, **23**, 141–146 (1999).
- 16) Ferrara S. D., Tedeschi, L., Frison, G. and Rossi, A.: Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. *J Forensic Sci*, **40**, 501–504 (1995).
- 17) Centers for Disease Control: Gamma hydroxybutyrate use - New York and Texas, 1995–1996. *J Am Med Assoc*, **277**, 1511 (1997).
- 18) Mozayani, A., Small, P. and De Cuir, L.: A fatality involving GHB. Program and Abstracts of Society of Forensic Toxicologists and the International Association of Forensic Toxicologists meeting, Albuquerque, NM, 1998, p. 127.
- 19) Arthur, C. L. and Pawliszyn, J.: Solid phase microextraction with thermal desorption using fused silica optical fibers. *Anal Chem*, **62**, 2145–2148 (1990).
- 20) Kumazawa, T., Lee, X.-P., Tsai, M.-C., Seno, H., Ishii, A. and Sato, K.: Simple extraction of tricyclic antidepressants in human urine by headspace solid-phase microextraction (SPME). *Jpn J Forensic Toxicol*, **13**, 25–30 (1995).
- 21) Kumazawa, T., Watanabe, K., Sato, K., Seno, H., Ishii, A. and Suzuki, O.: Detection of cocaine in human urine by solid-phase microextraction and capillary gas chromatography with

- nitrogen-phosphorus detection. *Jpn J Forensic Toxicol*, **13**, 207–210 (1995).
- 22) Seno, H., Kumazawa, T., Ishii, A., Nishikawa, M., Watanabe, K., Hattori, H. and Suzuki, O.: Detection of some phenothiazines by headspace solid phase microextraction (SPME) and gas chromatography. *Jpn J Forensic Toxicol*, **14**, 30–34 (1996).
 - 23) Ishii, A., Seno, H., Kumazawa, T., Nishikawa, M., Watanabe, K., Hattori, H. and Suzuki, O.: Simple clean-up of methamphetamine and amphetamine in human urine by direct-immersion solid phase micro extraction (DI-SPME). *Jpn J Forensic Toxicol*, **14**, 228–232 (1996).
 - 24) Guan, F., Watanabe, K., Ishii, A., Seno, H., Kumazawa, T., Hattori, H. and Suzuki, O.: Headspace solid-phase microextraction and gas-chromatographic determination of dinitroaniline herbicides in human blood, urine and environmental water. *J Chromatogr B*, **714**, 205–213 (1998).
 - 25) Giarman, N. J. and Roth, R. H.: Differential estimation of gamma-butyrolactone and gamma-hydroxybutyric acid in rat blood and brain. *Science*, **145**, 583–584 (1964).
 - 26) Pol, W., Kleijn, E. and Lauw, M.: Gas chromatographic determination and pharmacokinetics of 4-hydroxybutyrate in dog and mouse. *J Pharmacokinet Biopharm*, **3**, 99–113 (1975).
 - 27) Doherty, J. D., Snead, O. C. and Roth, R. H.: A sensitive method for quantitation of γ -hydroxybutyric acid and γ -butyrolactone in brain by electron capture gas chromatography. *Anal Biochem*, **69**, 268–277 (1975).
 - 28) Lettieri, J. T. and Fung, H.-L.: Evaluation and development of gas chromatographic procedures for the determination of γ -hydroxybutyric acid and γ -butyrolactone in plasma. *Biochem Med*, **20**, 70–80 (1978).
 - 29) Ferrara, S. D., Tedeschi, L., Frison, G., Castagna, F., Gallimberti, L., Giorgetti, R., Gessa, G. L. and Palatini, P.: Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. *J Pharmaceut Biomed Anal*, **11**, 483–487 (1993).
 - 30) Dion, A. and Jubinville, S.: Une nouvelle méthode simple pour dépister et quantifier l'acide gamma-hydroxybutyrique (GHB) dans le sang et l'urine par chromatographie en phase gazeuse. *Can Soc Forensic Sci J*, **31**, 303–312 (1998).
 - 31) Eli, M. and Cattabeni, F.: Endogenous γ -hydroxybutyrate in rat brain areas: postmortem changes and effects of drugs interfering with γ -aminobutyric acid metabolism. *J Neurochem*, **41**, 524–530 (1983).
 - 32) Ehrhardt, J. D., Vayer, P. and Maitre, M.: A rapid and sensitive method for the determination of γ -hydroxybutyric acid and trans- γ -hydroxycrotonic acid in rat brain tissue by gas chromatography/mass spectrometry with negative ion detection. *Biomed Environ Mass Spectrom*, **15**, 521–524 (1988).
 - 33) Gibson, K. M., Aramaki, S., Sweetman, L., Nyhan, W. L., DeVivo, D. C., Hodson, A. K. and Jakobs, C.: Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. *Biomed Environ Mass Spectrom*, **19**, 89–93 (1990).
 - 34) Louagie, H. K., Verstraete, A. G., De Soete, C. J., Baetens, D. G. and Calle P. A.: A sudden

awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. *J Toxicol Clin Toxicol*, **35**, 591–594 (1997).

- 35) Elian, A. A.: A novel method for GHB detection in urine and its application in drug-facilitated sexual assaults. *Forensic Sci Int*, **109**, 183–187 (2000).
- 36) Aspelund, H., Krogh, M. and Christophersen, A. S.: Analysis of GHB in whole blood by head-space solid-phase microextraction (SPME) and capillary gas chromatography. Programme and Abstracts of the 38th meeting of the International Association of Forensic Toxicologists, Helsinki, Finland, 2000, p. 115.